Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
GIFLF
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
finance.yahoo.comPOSITIVO
Are Options Traders Betting on a Big Move in Grifols Stock?
Investors in Grifols, S.A. GRFS need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 20, 2026 $2 Call had some of the highest implied volatility of all equity options today. What is…
Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings
Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating toda…
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
European equities traded in the US as American depositary receipts were tracking modestly higher lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now? Let's…
European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a cl…
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health
Toronto, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The union that represents Canadian Blood Services (CBS) workers in Ontario is calling for an immediate termination of the blood-plasma collection contract with for-profit Spanish pharmaceutical co…
European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading
European equities traded in the US as American depositary receipts were edging higher late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
FOXO Technologies Inc. WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.'s (OTC: FOXOD/FOXO) ( "FOXO") subsidiary, Vector BioSource, Inc. ("Vector") today announced that it has entered into a definitive agreemen…
Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...
This article first appeared on GuruFocus. Revenue: EUR3,574 million for the first half, up 2.6% at constant currency. Biopharma Revenue Growth: 5.4% growth at constant currency. Adjusted EBITDA: EUR472 million in Q2, EUR854 million for the…
Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therap…
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
European equities traded in the US as American depositary receipts started the week slightly higher PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
European equities traded in the US as American depositary receipts started the week lower late Monda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols, S.A. One trial, SIGMA, will evaluate Grifols' intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary immunod…
European Equities Traded in the US as American Depositary Receipts Advance Wednesday
European equities traded in the US as American depositary receipts were rising on Wednesday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment
Grifols (NASDAQ:GRFS) is one of the top value stocks to buy under $10. On June 15, Grifols launched FESILTY in the US for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency/CFD, excluding dysfibri…
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols, S.A. The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S. FESILTY complements Grifols' bleeding manage…
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late M PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks. TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to…
How The Grifols (BME:GRF) Investment Story Is Shifting With New Analyst Caution
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Analysts have trimmed their fair value price target for Grifols fro…
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending slightly higher lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European Equities Traded in US as ADRs Rise in Wednesday Trading
European equities traded in the US as American depositary receipts rose Wednesday with the S&P Europ PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Company Logo The kernicterus market is experiencing growth, fueled by an increase in neonatal jaundice cases, particularly among preterm infants. Major drivers include advancements in neonatal screening protocols and the development of non…
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
European equities traded in the US as American depositary receipts were heading higher late Monday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Latest] Global Intravenous (IV) Fluid Bags Market Size/Share Worth USD 5.46 Billion by 2035 at a 6.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Intravenous (IV) Fluid Bags Market size & share revenue was valued at approximately US…
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
European equities traded in the US as American depositary receipts opened the week on a flat note Mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Grifols (BME:GRF) Valuation Check After Mixed Short And Long Term Share Price Performance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Grifols Stock Is on Investors’ Radar Grifols (BME:GRF) has drawn fresh attention after a period where returns have diverged acr…
Grifols Q1 revenue misses consensus, net profit jumps
Investing.com -- Grifols shares fell 0.8% after the Spanish plasma products maker reported first-quarter revenues of €1.7 billion, a 3.3% increase on a constant currency basis but slightly below analyst consensus of €1.72 billion, as China…
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
DelveInsight Business Research LLP The hepatic encephalopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, cirrhosis, and alcohol-related liver disorders worl…
European Equities Traded in the US as American Depositary Receipts Start Week Lower
European equities traded in the US as American depositary receipts kicked off the week lower late Mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaini PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Is Grifols (BME:GRF) A Potential Opportunity After A 59% Five Year Share Price Slide
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether Grifols at around €8.95 is a bargain or a value trap, you are not alone. The stock has been volatile,…